Western Wealth Management LLC Grows Stock Position in AbbVie Inc. $ABBV

Western Wealth Management LLC boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 54.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 36,815 shares of the company’s stock after purchasing an additional 13,001 shares during the quarter. Western Wealth Management LLC’s holdings in AbbVie were worth $8,007,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at approximately $28,000. Imprint Wealth LLC increased its stake in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID increased its stake in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie during the 4th quarter worth $31,000. Finally, WestEnd Advisors LLC boosted its position in shares of AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Get AbbVie alerts:

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved RINVOQ® for severe alopecia areata in adults and adolescents aged 12 and older. The Phase 3 program demonstrated statistically significant scalp, eyebrow, and eyelash hair regrowth, including complete scalp regrowth for some patients. The approval expands RINVOQ’s commercial opportunity in Europe. RINVOQ alopecia areata approval
• Positive Sentiment: RINVOQ also received EU approval for non-segmental vitiligo, making it the first and only systemic treatment approved for that condition in the region. The decision was supported by positive Phase 3 repigmentation data and could further diversify RINVOQ growth. RINVOQ vitiligo approval
• Positive Sentiment: AbbVie began a first-in-human Phase 1 trial of ABBV-859, providing an early-stage pipeline catalyst. The program is not expected to affect near-term earnings, but investors may view it as evidence of continued investment in long-term growth. ABBV-859 Phase 1 trial
• Positive Sentiment: Unusually heavy call-option buying and a modest increase in an analyst’s 2027 earnings forecast indicate that some traders and analysts remain bullish on AbbVie’s longer-term earnings outlook.
• Neutral Sentiment: Allergan Aesthetics will hold its annual JUVÉDERM® Day on August 19, supporting consumer engagement and the aesthetics franchise, although the promotional event is unlikely to materially change near-term financial results. JUVÉDERM Day announcement
• Neutral Sentiment: Investors are also focused on AbbVie’s second-quarter earnings report due July 31. A slight reduction in one 2026 earnings estimate was offset by a higher 2027 forecast, leaving expectations mixed ahead of the report.
• Negative Sentiment: AbbVie’s proposed acquisition of Apogee Therapeutics faces an investigation into the deal’s price and transaction process. While the review does not establish wrongdoing, it introduces regulatory and execution uncertainty around the transaction. Apogee transaction investigation
• Negative Sentiment: After a strong multi-year rally, valuation concerns and potential profit-taking may be pressuring ABBV, particularly with the shares trading near their 52-week high and at a rich earnings multiple.

Analyst Ratings Changes

Several research firms recently issued reports on ABBV. JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Evercore set a $235.00 target price on shares of AbbVie in a report on Friday, May 15th. Wells Fargo & Company raised their price target on shares of AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, July 10th. Cantor Fitzgerald lifted their price target on shares of AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, July 6th. Finally, UBS Group upped their price objective on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $269.29.

Get Our Latest Research Report on AbbVie

AbbVie Trading Down 2.2%

NYSE:ABBV opened at $257.57 on Friday. AbbVie Inc. has a 12-month low of $187.62 and a 12-month high of $267.47. The firm has a market cap of $455.07 billion, a PE ratio of 126.88, a price-to-earnings-growth ratio of 0.87 and a beta of 0.30. The stock has a fifty day moving average price of $238.39 and a 200 day moving average price of $223.86.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.46 EPS. Equities analysts forecast that AbbVie Inc. will post 14.14 EPS for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is 340.89%.

AbbVie Company Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Read More

• Five stocks we like better than AbbVie
• Microsoft Just Flipped the AI Spending Narrative Overnight
• Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
• Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
• Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.